Ind-Swift Laboratories Ltd

Ind-Swift Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Ind-Swift Laboratories Ltd

₹ 96.2 2.18%
26 Nov 11:25 a.m.
indswiftlabs.com BSE: 532305 NSE: INDSWFTLAB
About

Incorporated in 1995, Ind-Swift Laboratories Ltd is in the business of Bulk Drugs & Pharmaceuticals[1]

Key Points

Business Overview:[1]
ISLL is a global manufacture of APIs, Intermediates and formulation (through group collaboration). It caters to the API needs of regulated markets including USFDA, EDQM, PMDA, ANVISA, EU-GMP, KFDA, NMO, ANSM, Cofepris, TGA, WHO, ROW. ISLL is present in all stages of drug substance/product including new chemical/molecular research to formulation development.
Company manufactures APIs towards Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Antimigraine, Parkinson’s Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence and Bone Resorption Inhibitor. It also holds global leadership positions in the Macrolide Antibiotic segment.

Website BSE NSE
  • Market Cap ₹ 785 Cr.
  • Current Price ₹ 96.2
  • High / Low ₹ 124 / 67.2
  • Stock P/E 26.5
  • Book Value ₹ 160
  • Dividend Yield 0.00 %
  • ROCE 0.78 %
  • ROE 0.18 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Stock is trading at 0.61 times its book value
  • Promoter holding has increased by 0.93% over last quarter.

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of -6.35% over past five years.
  • Company has a low return on equity of 8.93% over last 3 years.
  • Earnings include an other income of Rs.269 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
310.21 312.69 304.25 310.34 289.71 287.51 528.57 33.17 11.96 124.66 138.24 152.73 152.64
251.45 258.93 240.58 250.05 224.02 235.82 437.36 42.91 23.76 131.31 147.44 149.13 151.17
Operating Profit 58.76 53.76 63.67 60.29 65.69 51.69 91.21 -9.74 -11.80 -6.65 -9.20 3.60 1.47
OPM % 18.94% 17.19% 20.93% 19.43% 22.67% 17.98% 17.26% -29.36% -98.66% -5.33% -6.66% 2.36% 0.96%
7.54 8.36 -16.44 5.61 7.40 7.11 458.23 11.14 13.01 15.91 220.34 14.58 17.86
Interest 23.98 22.38 21.82 20.38 21.14 21.05 2.96 0.17 0.41 10.03 -26.76 1.15 2.01
Depreciation 16.41 15.39 9.29 13.89 13.19 13.56 19.55 0.25 0.22 5.81 7.44 6.68 6.98
Profit before tax 25.91 24.35 16.12 31.63 38.76 24.19 526.93 0.98 0.58 -6.58 230.46 10.35 10.34
Tax % 2.16% -13.43% 255.40% 45.02% 17.88% 19.31% 6.29% -3.06% 31.03% -16.41% 3.55% 16.52% 22.24%
25.34 27.50 -25.12 17.24 31.66 19.42 493.68 0.94 0.41 -5.49 222.27 8.77 7.99
EPS in Rs 4.29 4.65 -4.25 2.92 5.36 3.29 83.55 0.16 0.07 -0.93 36.67 1.45 0.98
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
965 660 653 716 765 757 780 891 1,039 1,207 1,709 562 568
906 571 546 610 631 630 635 709 837 978 1,403 581 579
Operating Profit 59 89 107 106 134 126 144 183 202 229 306 -19 -11
OPM % 6% 13% 16% 15% 18% 17% 19% 21% 19% 19% 18% -3% -2%
-19 -31 1 15 16 120 33 23 37 7 476 305 269
Interest 117 117 106 88 28 92 107 100 96 92 104 3 -14
Depreciation 66 84 85 88 87 104 90 87 131 57 80 24 27
Profit before tax -142 -143 -83 -55 36 50 -20 18 13 87 598 258 245
Tax % -14% -17% -29% -29% 39% 42% 7% 117% 117% 45% 10% 3%
-122 -119 -59 -39 22 29 -21 -3 -2 48 539 250 234
EPS in Rs -29.79 -29.14 -14.33 -8.75 4.85 6.09 -3.59 -0.53 -0.36 8.06 91.18 41.32 38.17
Dividend Payout % -0% -0% -0% -0% -0% -0% -0% -0% -0% -0% -0% -0%
Compounded Sales Growth
10 Years: -2%
5 Years: -6%
3 Years: -19%
TTM: -34%
Compounded Profit Growth
10 Years: 7%
5 Years: 16%
3 Years: 11%
TTM: -81%
Stock Price CAGR
10 Years: 12%
5 Years: 9%
3 Years: 14%
1 Year: -3%
Return on Equity
10 Years: 2%
5 Years: 6%
3 Years: 9%
Last Year: 0%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 41 42 42 45 46 48 60 60 60 60 67 69 82
Reserves 684 553 476 486 507 540 581 544 541 622 745 1,104 1,226
1,355 1,413 1,457 1,242 1,083 1,148 1,031 1,005 953 862 217 41 22
258 236 240 364 387 188 198 210 247 280 432 224 215
Total Liabilities 2,339 2,244 2,215 2,138 2,023 1,924 1,870 1,818 1,801 1,824 1,460 1,438 1,544
1,174 1,117 1,099 1,042 934 914 843 753 630 587 192 273 285
CWIP 78 113 78 70 69 20 11 19 10 8 51 -0 -0
Investments 17 18 18 18 18 19 17 36 29 30 112 213 312
1,070 997 1,020 1,007 1,002 972 998 1,011 1,131 1,199 1,106 952 947
Total Assets 2,339 2,244 2,215 2,138 2,023 1,924 1,870 1,818 1,801 1,824 1,460 1,438 1,544

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
-0 98 79 96 73 -64 125 135 150 195 -187 -25
-0 -35 -29 -31 -17 -12 -9 -10 5 -13 -28 -110
-0 -64 -48 -69 -62 100 -133 -124 -141 -186 657 69
Net Cash Flow -0 -1 3 -4 -6 23 -17 1 14 -4 443 -66

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 168 215 208 182 194 169 186 177 160 153 67 107
Inventory Days 182 312 368 305 291 284 315 301 288 242 31 145
Days Payable 103 120 137 91 118 114 124 111 118 113 122 140
Cash Conversion Cycle 247 407 439 396 367 339 377 367 330 282 -24 112
Working Capital Days 129 141 -26 -97 -49 217 248 253 253 234 7 115
ROCE % 0% 1% 2% 2% 4% 4% 5% 7% 7% 13% 21% 1%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
42.01% 42.01% 42.01% 42.01% 42.01% 42.01% 42.01% 42.01% 42.01% 40.94% 40.94% 39.49%
0.04% 0.00% 0.08% 0.17% 0.31% 0.26% 1.27% 0.65% 0.46% 3.07% 4.27% 14.80%
19.49% 19.49% 19.49% 19.49% 18.73% 8.03% 0.94% 0.94% 0.94% 0.91% 0.91% 0.68%
38.48% 38.52% 38.44% 38.34% 38.96% 49.72% 55.81% 56.41% 56.61% 55.08% 53.88% 45.02%
No. of Shareholders 24,45623,39722,96225,40524,63322,43925,46128,88328,75228,11728,70943,780

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • Nov 2020
    Transcript
    Notes
    PPT
  • Jul 2020
    Transcript
    Notes
    PPT